Document:

exv10w2

 

EXHIBIT 10.2

DEAN FOODS COMPANY

DEFERRED STOCK UNIT (“DSU”) AWARD AGREEMENT

     This AGREEMENT (this “Agreement”), effective as of the date indicated on
the attached Notice of Grant, is made and entered into by and between Dean
Foods Company, a Delaware corporation (the “Company”), and the individual named
on the attached Notice of Grant (“you”).

WITNESSETH:

     WHEREAS, the Board of Directors of the Company has adopted and approved
the Dean Foods Company Second Amended and Restated 1989 Stock Awards Plan (the
“Plan”), which Plan was approved as required by the Company’s stockholders and
provides for the grant of Options, Restricted Stock and other stock-based
Awards to certain selected Employees and Non-Employee Directors of the Company
and its Subsidiaries. Capitalized terms used and not otherwise defined in this
Agreement shall have the meanings set forth in the Plan; and

     WHEREAS, the Awards provided for under the Plan are intended to comply
with the requirements of Rule 16b-3 under the Exchange Act; and

     WHEREAS, the Committee has selected you to participate in the Plan and has
awarded the deferred stock units (“DSUs”) described in this Agreement to you.

     NOW, THEREFORE, in consideration of the foregoing and of the mutual
covenants and agreements herein contained, and as an inducement to you to
continue as an employee of the Company (or its Subsidiaries), you and the
Company hereby agree as follows:

     1. Grant of Award. The Company hereby grants to you and you hereby
accept, subject to the terms and conditions set forth in the Plan and in this
Agreement, the number of DSUs shown on the attached Notice of Grant, effective
as of the date indicated on the attached Notice of Grant (the “Date of Grant”).
Each DSU represents the right to receive one share of the Company’s Common
Stock, subject to the terms and conditions set forth in the Plan and in this
Agreement. The shares of Common Stock that are issuable upon vesting of the
DSUs granted to you pursuant to this Agreement are referred to in this
Agreement as “the Shares.” Subject to the provisions of Sections 2(c), 3(c)
and 7 hereof, this Award of DSUs is irrevocable and is intended to conform in
all respects with the Plan.

     2. Vesting.

          (a) Regular Vesting. Except as otherwise provided in the Plan or in this
Section 2, your DSUs will vest ratably in five equal annual increments
commencing on the first anniversary of the Date of Grant.

2004 Grant — V.1

Dairy Group and Corporate

 

 

          (b) Accelerated Vesting.

               (1) Notwithstanding the vesting schedule in Section 2(a) above, 100% of
the unvested DSUs subject to this Award will become fully vested, on the date
specified below, if the Volume Weighted Average Price (as defined below) of the
Company’s Common Stock equals or exceeds $47.41 per share for any 60
consecutive trading days (the “Stock Performance Target”). For purposes of
this Agreement, “Volume Weighted Average Price” means, for any given 60
consecutive trading days:

	 	(i)	 	the aggregate sales price of all
trades of Common Stock during such 60 day period,
	 
	 	 	 	divided by
	 
	 	(ii)	 	the total number of shares of Common
Stock traded during such 60 day period.

If the Stock Performance Target is achieved, 100% of your unvested DSUs subject
to this Award will become automatically vested on the later of (i) July 13,
2006, or (ii) the trading day on which the Stock Performance Target is
achieved. The failure of the Common Stock to achieve the Stock Performance
Target will not prevent your DSUs from vesting in accordance with Section 2(a)
or 2(b)(2) of this Agreement.

               (2) In addition to the vesting provisions contained in Sections 2(a) and
2(b)(1) above, your DSUs will automatically and immediately vest in full upon a
Change in Control.

          (c) Forfeiture of Unvested DSUs. Notwithstanding the provisions of
Sections 2(a) and 2(b) above or any provisions of the Plan to the contrary, if
your employment with the Company or any Subsidiary terminates for any reason
(including, without limitation, by reason of your death, permanent or total
disability, Qualifying Retirement or other retirement) before all or any
portion of the DSUs subject to this Award have vested, the unvested DSUs will
be immediately forfeited and neither you nor your estate will have any further
rights to such unvested DSUs or the Shares represented by those forfeited DSUs.

     3. Distributions of Shares.

          (a) Distribution Upon Vesting. Unless you have made a proper deferral
election pursuant to Section 3(b) below, the Company will distribute to you (or
to your estate in the event that your death occurs after a vesting date but
before distribution of the corresponding Shares), as soon as administratively
practicable after each vesting date, the Shares of Common Stock represented by
the DSUs that vested on such vesting date.

          (b) Deferral of Distributions. Notwithstanding the distribution dates
specified in Section 3(a) above, you may elect, on or before April 30, 2004, to
defer receipt of all or a portion of your Shares until a later date.
Specifically, you may elect to defer receipt of all or a

2004 Grant — V.1

Dairy Group and Corporate

-2-

 

portion of your Shares until one of the following dates (such election
being referred to in this Agreement as your “Deferral Election”):

	 	(i)	 	the 5th anniversary of the Date of Grant (January 13, 2009),
	 
	 	(ii)	 	the 10th anniversary of the Date of Grant (January 13, 2014),
	 
	 	(iii)	 	the termination of your employment
with the Company and its Subsidiaries,
	 
	 	(iv)	 	the earlier of the 5th anniversary of
the Date of Grant or the termination of your employment
with the Company and its Subsidiaries, or
	 
	 	(v)	 	the earlier of the 10th anniversary
of the Date of Grant or the termination of your
employment with the Company and its Subsidiaries.

If you elect to defer receipt of all or a portion of your Shares until one of
the above dates, you must also specify how you wish your Shares to be
distributed in the event of a Change in Control. Specifically, you must
indicate whether, in the event of a Change in Control, you wish to override
your previous Deferral Election and receive your Shares upon the Change in
Control, or continue to receive your Shares in accordance with your initial
Deferral Election.

     YOU MUST SUBMIT THE ATTACHED ELECTION FORM INDICATING WHETHER YOU WISH TO
DEFER. YOUR ELECTION TO DEFER RECEIPT OF ALL OR A PORTION OF YOUR SHARES CAN
ONLY BE MADE BY TIMELY SUBMITTING THE ATTACHED ELECTION FORM. EVEN IF YOU DO
NOT WISH TO DEFER RECEIPT OF YOUR SHARES, YOU STILL MUST SUBMIT AN ELECTION
FORM. ALL ELECTION FORMS MUST BE RECEIVED BY THE COMPANY ON OR BEFORE APRIL
30, 2004.

     If you elect to defer receipt of less than 100% (the “Deferred
Distribution Percentage”) of your Shares, you will receive as soon as
practicable after each vesting date the remaining percentage of the Shares
represented by the DSUs that vested on such date. If such number would result
in the right to receive a fractional share, the number of shares to be issued
shall be decreased to the next lower number of whole shares.

     For purposes of this Agreement, (i) the deferred distribution date that
you elect is referred to as the “Deferred Distribution Date,” and (ii) the
period between the date that any DSU vests and the Deferred Distribution Date
for the Shares represented by that DSU is referred to as a “Deferral Period”.

          (c) Forfeiture of Shares. Notwithstanding any provision of this Agreement
or the Plan to the contrary, if you are discharged from the employment of the
Company or any of its Subsidiaries for Cause (as defined below), your rights in
your DSUs (whether vested or unvested) and your right to receive any
undistributed Shares (whether the distribution has been deferred or not) will
be immediately and permanently forfeited. For purposes of this Agreement, your
discharge will be deemed to be “for Cause” only if you have (i) misappropriated
funds or

2004 Grant — V.1

Dairy Group and Corporate

-3-

 

property of the Company or any Subsidiary to your personal use, or (ii)
willfully and without authorization disclosed Confidential Information (as
defined below) that resulted in or could reasonably result in material harm to
the Company or any Subsidiary, or (iii) been convicted of a felony, or (iv)
violated the Company’s Code of Ethics. The determination of whether you have
been discharged for Cause will be determined by the Board or the Committee.
For purposes of this Agreement, “Confidential Information” shall mean all
business records, trade secrets, know-how, customer lists or compilations,
terms of customer agreements, sources of supply, pricing or cost information,
financial information or personnel data and other confidential or proprietary
information used and/or obtained by you in the course of your employment with
the Company or any Subsidiary; provided that the term “Confidential
Information” will not include information which (i) is or becomes publicly
available other than as a result of a disclosure by you which is prohibited by
this agreement or by any other legal, contractual or fiduciary obligation that
you may owe to the Company or any Subsidiary, or (ii) is widely known within
one or more of the industries in which the Company or any Subsidiary operates,
or you can demonstrate was otherwise known to you prior to becoming an employee
of the Company or any Subsidiary, or (iii) is or becomes available to you on a
nonconfidential basis from a source (other than the Company or any Subsidiary,
including any employee thereof) that is not prohibited from disclosing such
information to you by a legal, contractual or fiduciary obligation to the
Company or any Subsidiary.

          (d) Compliance With Law. The Company shall not be obligated to issue your
Shares upon the vesting of any DSU or on any Deferred Distribution Date (or
otherwise) unless the issuance and delivery of such Shares complies with all
relevant provisions of law and other legal requirements including, without
limitation, any applicable federal or state securities laws and the
requirements of any stock exchange upon which shares of the Company’s Common
Stock may then be listed. As a condition to the distribution of your Shares,
the Company may require you to make such representations and warranties as may
be necessary to assure the availability of an exemption from the registration
requirements of applicable federal or state securities laws. The Company shall
not be liable for refusing to issue your Shares if the Company cannot obtain
authority from the appropriate regulatory bodies deemed by the Company to be
necessary to lawfully distribute your Shares. In addition, the Company shall
have no obligation to you, express or implied, to list, register or otherwise
qualify any of your Shares of Common Stock.

4. Other Rights.

          (a) Dividends. If at any time during a Deferral Period (as defined in
Section 3 above), the Company pays a dividend on its Common Stock, then on each
such dividend payment date (each, a “Dividend Payment Date”), you will
automatically receive an additional number of DSUs equal to the Total Dividend
Value divided by the Fair Market Value of the Company’s Common Stock on the
Dividend Payment Date. The additional DSUs paid on each Dividend Payment Date
pursuant to the immediately preceding sentence are referred to in this
Agreement as “Dividend DSUs.” For each dividend paid during a Deferral Period,
the “Total Dividend Value” will be an amount equal to (i) the per share value
of such dividend, multiplied by (ii) the number of Shares that you have
deferred (pursuant to a valid Deferral Election) and not yet received (such
Shares being referred to in this Agreement as the “Deferred Shares”).

2004 Grant — V.1

Dairy Group and Corporate

-4-

 

Shares represented by Dividend DSUs will vest and be distributed on the
same date as the underlying Deferred Shares.

          (b) Other Shareholder Rights. Except as set forth in Section 4(a) above
and in the Plan, neither you nor any person claiming under or through you shall
be, or have any of the rights or privileges of, a stockholder of the Company in
respect of the Shares issuable pursuant to this Award unless and until your
Shares shall have been delivered to you.

     5. Tax Withholding. Any provision of this Agreement to the contrary
notwithstanding, the Company may take such steps as it deems necessary or
desirable for the withholding of any taxes that it is required by law or
regulation of any governmental authority, federal, state or local, domestic or
foreign, to withhold in connection with vesting of any DSU or issuance of any
of the Shares subject thereto.

     6. Transfer of DSUs. The DSUs granted herein are not transferable except
in accordance with the provisions of the Plan.

     7. Covenant Not to Compete or Solicit. In consideration of this Award,
you hereby agree that, during the term of your employment with the Company or
any Subsidiary and for a period of two years thereafter, you will not, directly
or indirectly, individually or on behalf of any person or entity other than the
Company or any of its Subsidiaries:

          (a) Become associated with (as defined below) any company or business
(other than the Company or any Subsidiary) engaged primarily in the
manufacture, distribution, sale or marketing of any of the Relevant Products
(as defined below) in any geographical area in which the Company or any of its
Subsidiaries operates;

          (b) Approach, consult, solicit business from, or contact or otherwise
communicate, directly or indirectly, in any way with any Customer (as defined
below) in an attempt to (1) divert business from, or interfere with any
business relationship of the Company or any of its Subsidiaries, or (2)
convince any Customer to change or alter any of such Customer’s existing or
prospective contractual terms and conditions with the Company or any
Subsidiary; or

          (c) Solicit, induce, recruit or encourage, either directly or indirectly,
any employee of the Company or any Subsidiary to leave his or her employment
with the Company or any Subsidiary or employ or offer to employ any employee of
the Company or any Subsidiary. For the purposes of this section, an employee
of the Company or any Subsidiary shall be deemed to be an employee of the
Company or any Subsidiary while employed by the Company and for a period of 60
days thereafter.

     For purposes of this Agreement, the following terms shall have the
meanings indicated:

     “associated with” means to become involved or act as an owner, partner,
stockholder, investor, joint venturer, lender, director, manager, officer,
employee, consultant, independent contractor, representative or agent.

2004 Grant — V.1

Dairy Group and Corporate

-5-

 

     “Customer” means all persons or entities who purchased any Relevant
Product from the Company or any Subsidiary during the term of your employment
with the Company or any Subsidiary.

     “Relevant Product(s)” means (i) milk and milk-based beverages, (ii) creams
and creamers, (iii) ice cream and ice cream novelties, (iv) ice cream mix, and
(v) cultured dairy products.

     Notwithstanding the foregoing, (1) the restrictions of this Section 7
shall terminate immediately if your employment with the Company or any
Subsidiary is involuntarily terminated by the Company or such Subsidiary
without Cause (as defined in Section 3(c) hereof), and (2) you are not
prohibited from owning, either of record or beneficially, not more than five
percent (5%) of the shares or other equity of any publicly traded company.
Your obligation under this Section 7 shall survive the vesting or forfeiture of
your DSUs and/or the distribution or forfeiture of the underlying Shares. The
provisions of this Section 7 are not intended to override, supercede, reduce,
modify or affect in any manner any other non-competition or non-solicitation
agreement between you and the Company or any Subsidiary. Any such covenant or
agreement shall remain in full force and effect in accordance with its terms.
Any breach of any provision of this Section 7 will result in immediate and
complete forfeiture of your unvested DSUs and your undistributed Shares, and
the Company will be entitled to injunctive and other relief to prevent or
enjoin any violation of the provisions of this Agreement.

     You acknowledge that you have given careful consideration to the
restraints imposed by this Agreement, and you fully agree that they are
necessary for the reasonable and proper protection of the business of the
Company and its Subsidiaries. You agree that each and every restraint imposed
by this Agreement is reasonable with respect to subject matter, time period,
and geographical area. Except as expressly set forth herein, the restraints
imposed by this Agreement shall continue during their full time periods and
throughout the geographical area set forth in this Agreement.

     If the restrictions of this Section 7 are deemed unenforceable as written,
the parties expressly authorize the court to revise, delete, or add to the
restrictions contained in this Section 7 to the extent necessary to enforce the
intent of the parties and to provide the goodwill, confidential information,
and other business interests of the Company and its Subsidiaries with effective
protection.

     8. Plan Incorporated. You accept the DSUs hereby granted subject to all
the provisions of the Plan, which, except as expressly contradicted by the
terms hereof, are incorporated into this Agreement, including the provisions
that authorize the Committee to administer and interpret the Plan and which
provide that the Committee’s decisions, determinations and interpretations with
respect to the Plan are final and conclusive on all persons affected thereby.

2004 Grant — V.1

Dairy Group and Corporate

-6-

 

     9. Miscellaneous.

          (a) No Guaranteed Employment. Nothing contained in this Agreement shall
affect the right of the Company to terminate your employment at any time, with
or without Cause, or shall be deemed to create any rights to employment on your
part. The rights and obligations arising under this Agreement are not intended
to and do not affect the employment relationship that otherwise exists between
the Company and you, whether such employment relationship is at will or defined
by an employment contract. Moreover, this Agreement is not intended to and
does not amend any existing employment contract between the Company and you.
To the extent there is a conflict between this Agreement and such an employment
contract, the employment contract shall govern and take priority.

          (b) Notices. Any notice to be given to the Company under the terms of
this Agreement shall be addressed to the Company at its principal executive
offices, and any notice to be given to you shall be addressed to you at the
address set forth on the attached Notice of Grant, or at such other address for
a party as such party may hereafter designate in writing to the other. Any
such notice shall be deemed to have been duly given if mailed, postage prepaid,
addressed as aforesaid.

          (c) Binding Agreement. Subject to the limitations in this Agreement on
the transferability by you of the Award granted herein, this Agreement shall be
binding upon and inure to the benefit of the representatives, executors,
successors or beneficiaries of the parties hereto.

          (d) Governing Law. The interpretation, performance and enforcement of
this Agreement shall be governed by the laws of the State of Delaware and the
United States, as applicable, without reference to the conflict of laws
provisions thereof.

          (e) Severability. If any provision of this Agreement is declared or found
to be illegal, unenforceable or void, in whole or in part, then the parties
shall be relieved of all obligations arising under such provision, but only to
the extent that it is illegal, unenforceable or void, it being the intent and
agreement of the parties that this Agreement shall be deemed amended by
modifying such provision to the extent necessary to make it legal and
enforceable while preserving its intent or, if that is not possible, by
substituting therefor another provision that is legal and enforceable and
achieves the same objectives.

          (f) Interpretation. All section titles and captions in this Agreement are
for convenience only, shall not be deemed part of this Agreement, and in no way
shall define, limit, extend or describe the scope or intent of any provisions
of this Agreement.

          (g) Entire Agreement. This Agreement constitutes the entire agreement
among the parties hereto pertaining to the subject matter hereof and supersedes
all prior agreements and understandings pertaining thereto.

          (h) No Waiver. No failure by any party to insist upon the strict
performance of any covenant, duty, agreement or condition of this Agreement or
to exercise any right or remedy consequent upon a breach thereof shall
constitute waiver of any such breach or any other covenant, duty, agreement or
condition.

2004 Grant — V.1

Dairy Group and Corporate

-7-

 

          (i) Counterparts. This Agreement may be executed in counterparts, all of
which together shall constitute one agreement binding on all the parties
hereto, notwithstanding that all such parties are not signatories to the
original or the same counterpart.

          (j) Relief. In addition to all other rights or remedies available at law
or in equity, the Company shall be entitled to injunctive and other equitable
relief to prevent or enjoin any violation of the provisions of this Agreement.

END OF AGREEMENT

2004 Grant — V.1

Dairy Group and Corporate

-8-

 

ELECTION FORM

ALL DSU RECIPIENTS MUST DELIVER THIS FORM TO LISA TYSON ON OR BEFORE APRIL 30,
2004.

	 	 	 	 	 	 	 
	 
	 	Option One:
	                    
	 	I do not wish to defer receipt of my Shares. I prefer to receive my Shares as they vest.
	 
	 	 	 	 	 	 
	 
	 	Option Two:
	                    
	 	I wish to defer receipt of _____% of my Shares until [select one]:
	 
	 	 	 	 	 	 
	

	 	                    
	 	(i)
	 	The 5th anniversary of the Date of Grant (January 13, 2009);
	 
	 	 	 	 	 	 
	

	 	                    
	 	(ii)
	 	The 10th anniversary of the Date of Grant (January 13, 2014);
	 
	 	 	 	 	 	 
	

	 	                    
	 	(iii)
	 	The termination of my employment with the Company and its Subsidiaries;
	 
	 	 	 	 	 	 
	

	 	                    
	 	(iv)
	 	The earlier of the 5th anniversary
of the Date of Grant (January 13, 2009) or the termination of my employment with the Company and its Subsidiaries; or
	 
	 	 	 	 	 	 
	

	 	                    
	 	(v)
	 	The earlier of the 10th anniversary
of the Date of Grant (January 13, 2014) or the termination of my employment with the Company and its Subsidiaries.

     Notwithstanding my deferral election above, if a Change in Control occurs
prior to the date indicated above, I want my deferral date to [select one]:

	 	 	 	 	 	 	 
	

	 	                    
	 	(i)
	 	remain the same; or
	 

	 	 	 	 	 	 
	

	 	                    
	 	(ii)
	 	be accelerated to the effective date of such Change in Control.
	

	 	 	 	 	 	 
	

	 	 	 	 	 	(Please note that if you chose Option One above — which is not
to defer receipt of your Shares but to receive them as they
vest — you will automatically receive your Shares upon a
Change in Control.)

	 	 	 
	

	 	SIGNATURE:                    
                    
                    
                    
                    
                    
	 

	 	 
	

	 	PRINTED NAME:                    
                    
                    
                    
                    
                    
	 

	 	 
	

	 	DATED:                    
                    
                    
                    
                    
                    

*Defined terms used in this Election Form shall have the meanings set forth in
the corresponding DSU Award Agreement.

2004 Grant — V.1

Dairy Group and Corporate<PAGE>

Exhibit 10.1

                        DEVELOPMENT AND LICENSE AGREEMENT

This Development and License Agreement (the "Agreement") is entered into as of
26th April, 2004 (the "Effective Date"), by and between ATS MEDICAL, INC. and
ERYSAVE AB. ATS and ErySave may be referred to in this Agreement, individually,
as a "party," and, collectively, as "parties.")

Witness that, WHEREAS

A.       ATS is a medical device company engaged in, among other things, the
         development, manufacture and commercialisation of medical and related
         products.

B.       ErySave is a technology company engaged in, among other things, the
         development of medical products and wishes to enter into this Agreement
         to complete their development, in collaboration with ATS, and to
         license ATS to develop, manufacture, import, export, market,
         distribute, sell and use the subject products.

C.       ATS wishes to collaborate with ErySave to complete the development of
         the products which are the subject of this Agreement and to market,
         distribute and sell those products on the terms set out in this
         Agreement.

In consideration of the mutual promises and agreements of the parties set out in
this Agreement, the receipt and sufficiency of which is acknowledged by the
parties, THE PARTIES AGREE as follows:

1.       DEFINITIONS

1.1      In this Agreement the capitalized terms defined below and
         parenthetically elsewhere shall have the meanings here or there
         supplied whenever such terms are used in their capitalised form:

1.1.1    Affiliate(s) means in respect of either party any corporation or other
         business entity which is part of the same enterprise grouping as the
         party and which controls, is controlled by, or is under common control
         with such party, where control means at least majority ownership or
         control of at least a majority of the voting shares or the power in
         fact to control management decisions.

1.1.2    Agreement means this agreement, all annexes, appendices and additions
         to this agreement, and all modifications, amendments, extensions and
         renewals of this agreement.

1.1.3    ATS means ATS Medical, Inc., a Minnesota corporation which has its
         principal place of business at 3905 Annapolis Lane, Suite 105,
         Minneapolis, Minnesota, 55447 USA.

1.1.4    CE Certification or CE-Mark means compliance with the European Union
         Medical Device Directive (93/42/EEC).

** The appearance of a double asterisk denotes confidential information that has
been omitted from the exhibit and filed separately, accompanied by a
confidential treatment request, with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                     - 1 -
<PAGE>

1.1.5    CE-Approved Prototype - the Prototype designed and/or manufactured in
         conformance with the Specifications and which has obtained CE
         Certification.

1.1.6    ErySave means ErySave AB, a Swedish corporation which has its principal
         place of business at IDEON, SE-223 70 Lund, Sweden.

1.1.7    Know-How means all present and future confidential and substantial
         information, research, studies, specifications, samples, materials,
         documents, trade secrets, data, methods, processes, and special
         abilities acquired, licensed, owned or controlled by or on behalf of
         ErySave concerning or relating to the PARSUS Technology, including but
         not limited to analytical and clinical data, product forms and
         specifications, methods of preparation, assembly and manufacture,
         information contained in registration dossiers, and all third party
         data relating to the PARSUS Technology to which ErySave has access.

1.1.8    License means the licenses granted by ErySave to ATS pursuant to Part 5
         of this Agreement

1.1.9    Licensed Field means the field of intra-operative cardiovascular
         surgery.

1.1.10   Net Sales means the gross revenues invoiced or otherwise receivable by
         ATS or its Affiliates in respect of revenues from Products that were
         made by (or were made under authority of) ATS or its Affiliates and
         were sold, leased, transferred or otherwise made available to
         independent third parties, less (i) reasonable, customary and usual
         trade or quantity discounts actually taken by customers, (ii) sales,
         use, value-added and excise taxes imposed and paid in respect of sales
         of Products and included in the invoice price, (iii) import and export
         duties or fees, and shipping and delivery charges; and (iv) refunds for
         customer returns.

1.1.11   PARSUS Technology means any device or method, as now existing or later
         developed, for separating particles from fluids using ultrasound,
         including, but not limited to, any device or method that is within the
         scope of any claim of PCT Patent Application Publication No. WO
         02/072235, filed March 11, 2002 and entitled "Device And Method For
         Separation."

1.1.12   Patents means those patent rights, patents applications and patents
         owned or controlled by ErySave or to which ErySave has acquired rights,
         and which claim any PARSUS Technology, including patents and patent
         rights deriving or issuing therefrom and all extensions, additions,
         reissues, continuations, continuations-in-part or divisions thereof and
         any substitute applications thereof and any protection certificate for
         any of the aforesaid and all other patents claiming priority with or
         from such patents anywhere in the world and all derivations,
         improvements or further developments thereof created by, applied for,
         granted to, acquired, controlled or licensed by ErySave after the date
         of this Agreement relating to the PARSUS Technology.

1.1.13   Product(s) means any device made from, made with, based on, containing,
         or incorporating PARSUS Technology, including but not limited to, the
         Prototype, restricted to applications and indications in the Licened
         Field where the development, manufacture, importation, export,
         marketing, distribution, sale or use involves in any

                                     - 2 -
<PAGE>

         way the Know-How or is dependent upon, covered by or within the scope
         of any claim or invention disclosed in the Patents.

1.1.14   Prototype means the ErySave fat emboli cleaner device known as
         "MindShield" presently under development and which includes a "Base
         Unit," a "Disposable Disc" and "Disposable Disc/Kit," which, upon
         completion of development, shall be deemed to be a Product.

1.1.15   Royalty means the royalty payable by ATS to ErySave pursuant to Part 7
         of this Agreement.

1.1.16   Specifications means the design requirements, functional requirements,
         testing procedures, quality assurance procedures, and documentation
         requirements for the Prototype or other Products as agreed upon by the
         parties.

1.1.17   Trademarks means the trademark or marks listed in Appendix 2 to this
         Agreement and such other of ErySave's trademarks or tradenames and such
         further identification and marks as ErySave may from time to time
         designate for use on, with or in relation to, among other things,
         Products.

2.       PROTOTYPE DEVELOPMENT PHASE

2.1      The Prototype Development Phase shall comprise the time period and
         relate to all work with respect to the development of the Prototype
         into a commercially viable Product. The Prototype Development Phase
         shall be deemed completed upon obtaining CE Certification for the
         Prototype. It is anticipated that obtaining CE Certification for the
         Prototype will be completed within twenty four (24) months from the
         date of execution of this Agreement.

2.2      ErySave shall, in accordance with a development plan and budget
         elaborated by ErySave in consultation with ATS, complete the
         development of the Prototype in accordance with the Specifications and
         provide the CE-Approved Prototype and/or its related design
         documentation to contract manufacturers to be chosen by agreement of
         both parties for the purpose of establishing full-scale production of
         the CE-Approved Prototype for commercial sale. ATS will, on request and
         at no additional cost to ErySave, provide reasonable assistance to
         ErySave in this process.

2.3      The parties shall, where appropriate or necessary and acting
         reasonably, elaborate and agree on the Specifications. Additionally,
         the parties shall establish target dates for completion of the
         development for the Prototype, the provision of the CE-Approved
         Prototype and/or its related design documentation to contract
         manufacturers for full-scale commercial production, and obtaining
         marketing authorization in the U.S., Europe and other markets for the
         CE-Approved Prototype.

2.4      ErySave shall be responsible for and shall bear all costs associated
         with obtaining a CE-Certification for the Prototype.

2.5      ErySave shall be responsible for achieving the development milestones
         set out in sub-paragraphs (b) - (g) of this paragraph as described in
         more detail in Appendix 4; and ATS shall pay ErySave the aggregate sum
         of SEK 10,000,000.00 in the following installments

                                     - 3 -
<PAGE>

         and based on the completion of the following milestones, regardless of
         the order in which each milestone is achieved:

                  (a)   Execution of this Agreement - SEK 1,430,000.

                  (b)   Completion of development of the Disposable Disc in
                        accordance with the Specifications - SEK 1,430,000. At a
                        minimum the Disposable Disc shall be a full-size disc
                        (5-1/2 inch or equivalent size) made of disposable
                        material (polymer or other) and shall incorporate
                        micromechanical channels in the Disposable Disc.

                  (c)   Completion of development of the Disposable Disc/Kit in
                        accordance with the Specifications - SEK 1,430,000. At a
                        minimum the Disposable Disc/Kit shall be a full-size
                        disc (5-1/2 inch or equivalent size) made of disposable
                        material with a lid attached to the disc, and shall
                        include tubing and flow control devices attached to the
                        disc/lid set, and shall have a throughput of a minimum
                        of one liter/hour, with a minimum fat emboli removal of
                        90%.

                  (d)   Completion of the GLP (Good Laboratory Practice) animal
                        studies for the Prototype needed for CE-Certification -
                        SEK 1,430,000.

                  (e)   Completion of development of the Base Unit in accordance
                        with the Specifications - SEK 1,430,000.

                  (f)   Completion of the transfer of manufacturing information
                        for the CE-Approved Prototype to selected contract
                        manufacturers for full-scale production of the
                        CE-Approved Prototype for commercial sale - SEK
                        1,430,000. Transfer of manufacturing information shall
                        be defined as the transfer from ErySave to the relevant
                        manufacturer or manufacturers of all documentation in
                        ErySave's possession or control which are relevant or
                        necessary for the manufacturing of all components
                        comprising the CE-Approved Prototype.

                  (g)   Receipt of CE-Mark Approval - SEK 1,420,000.

2.6      ErySave shall invoice ATS for each installment amount payable under
         paragraph 2.5 upon the occurrence of the events specified and ATS shall
         make payment of such invoices within thirty days of receipt of the
         invoice. Interest shall accrue and be paid by ATS on all overdue
         invoice amounts at the rate of 1.0% simple interest per month (12%
         simple interest per annum) until paid.

2.7      All amounts payable under this Part 2 shall be paid in full without any
         withholding or deduction. ErySave shall return any amounts that are not
         required for expenses related to the achievement of the development
         milestones to ATS.

2.8      ATS shall make all payments required to be made under this Part 2 to
         ErySave in Swedish Kronor (SEK).

                                     - 4 -
<PAGE>

2.9      ErySave shall have no obligation to manufacture and supply any
         Prototype or CE-Approved Prototype for use by ATS other than as may be
         set out herein or mutually agreed in writing.

2.10     Notwithstanding anything to the contrary in this Agreement, upon thirty
         (30) days prior written notice and with the prior written consent from
         ATS, ErySave may subcontract the performance of all its obligations for
         the Prototype Development Phase under this Part 2.

2.11     The parties shall, as far as reasonably practicable, carry out the
         Prototype Development Phase in a timely manner and using their
         commercially reasonable efforts.

2.12     The parties shall immediately advise one another of any anticipated
         delay in meeting the schedule or milestone during the Prototype
         Development Phase.

2.13     In the event of any anticipated or possible delay which has the
         potential to cause substantial inconvenience, cost or loss to the
         parties or either of them, the parties shall forthwith consult with one
         another as to ways of avoiding the delay and of dealing with the
         consequences of the delay.

2.14     The parties acknowledge their mutual understanding that the Prototype
         Development Phase involves development work, the progress and results
         of which cannot necessarily be anticipated or planned for in advance,
         and that there needs to be a high degree of mutual flexibility in terms
         of scheduling, support and resources, particularly in respect of
         unforeseen delays and other difficulties which might arise.

2.15     In the event ATS develops additional Products and elects to involve
         ErySave in any related development process, the parties will follow a
         similar product development phase as set forth in this Part 2 followed
         by a commercial phase as set forth in Part 3. The specific terms,
         conditions and requirements for completing the product development
         phase and commercial phase for any future Products involving ErySave
         are to be determined by mutual agreement of the parties.

3.       COMMERCIAL PHASE

3.1      The Commercial Phase for the CE-Approved Prototype shall commence upon
         the completion of the Prototype Development Phase and shall involve all
         duties and obligations as set forth in this Part 3. During the
         Commercial Phase, ATS shall undertake the tasks described in this
         Section 3; and the parties shall elaborate and agree on target launch
         dates for the U.S., major European markets, and other markets.

3.2      ATS shall be responsible for and shall bear all costs associated with
         obtaining the permits, licences, registrations, certificates, approvals
         and other regulatory authorisations required to manufacture,
         distribute, market, sell and use the CE-Approved Prototype, including
         without limitation, obtaining regulatory approvals in all non-CE
         countries and for any local work needed to transform the CE-Mark into a
         marketing authorization in any other countries. ErySave will, on
         request, provide reasonable assistance to ATS and share with ATS any
         required information in ErySave's possession or control.

                                     - 5 -
<PAGE>

3.3      ErySave shall co-operate with ATS by providing data and information
         produced in the course of ErySave's development work on the Prototype
         as may assist ATS in obtaining the authorisations referred to in
         paragraph 3.2. ATS will, on request, share with ErySave all information
         in ATS' possession or control arising out of ATS activities in
         obtaining the authorizations referred to in paragraph 3.2 for use by
         ErySave with respect to any CE-Approved Product.

3.4      ErySave and ATS shall be jointly responsible for procuring the
         manufacturing of the Disposable Discs for the CE-Approved Prototype and
         for ensuring the supply of the Disposable Discs for the CE-Approved
         Prototype to ATS's contract manufacturer(s).

3.5      ATS shall be responsible for procuring the commercial manufacture and
         supply of remaining components of the CE-Approved Prototype and for
         assembly, sterilization and packaging of the final components of the
         CE-Approved Prototype; and ErySave shall assist ATS in the transfer and
         set-up of the processes and methods which will be required to
         manufacture the CE-Approved Prototypes by a commercial contract
         manufacturer or manufacturers agreed to in writing by both parties.

3.6      ATS shall use commercially reasonable efforts to diligently pursue the
         commercialization of the CE-Approved Prototypes and shall meet the
         requirements of the market by making or having made and offering or
         having offered for sale adequate quantities of the CE-Approved
         Prototypes on commercially reasonable terms.

3.7      ATS shall at all times in relation to the CE-Approved Prototypes
         conduct itself and use efforts substantially consistent with like
         conduct and effort devoted to other products of similar commercial
         potential or significance.

3.8      ATS shall use commercially reasonable efforts to actively and
         effectively promote, market, distribute and sell the CE-Approved
         Prototypes at its own expense and for its own account, maintain an
         adequate sales force, assign sufficient staff to the CE-Approved
         Prototypes for the purposes of this Agreement, establish and maintain a
         system of after-sales support for the CE-Approved Prototypes, maintain
         sufficient stocks of the CE-Approved Prototypes, and properly handle
         and store the CE-Approved Prototypes. In markets where ATS does not
         have its own representation, ErySave and ATS shall be jointly
         responsible for the commercialisation of the Product.

3.9      ATS shall conduct its advertising, promotional and marketing activities
         consistent with industry practices and may make use of marketing
         information, materials and documentation and product and technical
         documentation, specifications, instructions for use, directions,
         indications and standards supplied by ErySave, if any.

3.10     ATS shall use commercially reasonable efforts to ensure that all the
         CE-Approved Prototypes are properly packaged and labelled and are
         accompanied by proper and sufficient manuals and other literature
         setting out and containing such clear and plain safety information,
         instructions and warnings as may be required by applicable law and as
         may be required or advisable in the circumstances. ATS shall not alter,
         remove or modify the CE-Approved Prototypes or any aspect of their
         safety systems or features, without the prior, specific, written
         permission of ErySave.

                                     - 6 -
<PAGE>

3.11     ATS shall use commercially reasonable efforts to substantially comply
         with all laws, rules, regulations and administrative directions
         concerning the production, marketing, distribution, sale and use of the
         CE-Approved Prototypes. ErySave shall, on request, provide reasonable
         assistance to ATS to enable compliance with all such laws, rules,
         regulations and administrative directions. Each of the parties shall
         promptly notify the other of changes or other developments in the
         applicable laws, rules, regulations and administrative directions of
         which it becomes aware and which are relevant to either parties'
         obligations under this Agreement.

3.12     ATS shall not distribute or sell any obsolete CE-Approved Prototypes or
         CE-Approved Prototypes with insufficient remaining shelf-life.

3.13     ATS shall prepare and deliver to ErySave at the commencement of this
         Agreement, and then periodically (at least yearly, but no more than
         quarterly), a report containing specific detail of ATS' future
         development, manufacturing, marketing, and sales activities, plans and
         projections relating to the CE-Approved Prototypes, together with a
         comparison of actual activities and results to the activities, plans
         and projections that had been predicted in the prior report. ErySave
         shall have the right to approve such future plans and projections,
         acting reasonably.

3.14     In addition to and without in any way limiting its obligations under
         this Part 3, ATS shall adhere to the following minimum marketing
         performance criteria described in more detail in Appendix 3:

                  a.    development of brochure(s) for the CE-Approved
                        Prototypes;

                  b.    development of sales training programs and
                        implementation of sales force training classes the
                        CE-Approved Prototypes;

                  c.    development of website content and relevant links for
                        the CE-Approved Prototypes;

                  d.    incorporation of graphics in ATS trade show exhibit
                        booths the CE-Approved Prototypes;

                  e.    inclusion of the CE-Approved Prototypes in cardiac
                        surgery symposia supported by ATS;

                  f.    hiring and training of manager for the CE-Approved
                        Prototypes;

                  g.    inclusion of the CE-Approved Prototypes in journal
                        advertising campaigns;

                  h.    development of a design and performance manual, and
                        development and maintenance of processes for order
                        entry, equipment service requests, etc. for the
                        CE-Approved Prototypes;

                  i.    During each twelve month period beginning twenty four
                        months after U.S. FDA approval, ATS shall make royalty
                        payment(s) at least equal to **.This amount will
                        increase ** for each subsequent year. For example the
                        amount will be ** in year one, ** in year two, ** in
                        year three and so on. If FDA approval has not been
                        received within twenty four months of CE Certification,
                        ATS shall make royalty payment(s) at least equal to **.
                        This amount will increase ** for each subsequent year
                        until FDA approval has been received (at which point the
                        amount will be increased to ** plus an extra ** for each
                        subsequent year.

                                     - 7 -
<PAGE>

3.15     ATS shall carry out its obligations under this Part 3 using
         commercially reasonable efforts, in a timely manner and at its own
         expense.

3.16     ATS shall report to ErySave, on a quarterly basis or as otherwise
         agreed upon by the parties, regarding the activities to be undertaken
         by ATS under this Part 3 and, to the extent permitted by law, shall
         share with ErySave all data and information relating to or arising from
         such activities.

4.       PROJECT GROUP AND REPORTING

4.1      Each party shall designate one person to be the focal point for contact
         between the parties in respect of the Products. Any change to the
         designations shall be by notice in writing to the other party.

4.2      The parties' designated persons appointed pursuant to this Part 4 shall
         form a Steering Committee consisting of at least one representative of
         ATS and one or more representative of ErySave. The Steering Committee
         shall meet in person or by telephone conference at such intervals as
         the designated persons may from time to time determine for the purposes
         of regular reporting regarding both the product development and
         commercial phases. In addition and without limiting the foregoing, with
         respect to the Prototype, the Steering Committee shall meet at a
         minimum once every two weeks via Webcast Conference Call and once every
         two months face-to-face to review matters during both the Prototype
         Development Phase and the Commercial Phase.

4.3      With respect to the Prototype, progress reviews shall include ErySave's
         Development Project Manager, ErySave's President, ATS's Medical PARSUS
         Product Manager, ATS's Vice President Marketing & Business Development,
         and others to be determined by mutual agreement of ErySave's President
         and ATS's Vice President Marketing & Business Development.

5.       GRANT OF LICENSE

5.1      ErySave hereby grants ATS, and ATS hereby accepts, the world-wide, and
         exclusive right and license under the Know-How and Patents to use and
         practise the PARSUS Technology to develop, manufacture, import, export,
         market, distribute, sell and use the CE-Approved Prototype and any
         future Products during the term of this Agreement.

5.2      ErySave hereby grants to ATS, and ATS hereby accepts, the world-wide,
         non-exclusive right and license to use the Trademarks on and in
         connection with the sale, offering for sale, distribution and
         advertising of the CE-Approved Prototype and any future Products during
         the term of this Agreement subject to the restrictions under Part 6.

5.3      ATS is authorized to sub-license its rights and obligations under this
         Agreement to sub-distributors, provided ATS remains liable for
         performance by all sub-licensees of all obligations sub-licensed and
         ATS informs ErySave of the identity of sub-licensees as soon as
         reasonably practicable following their agreement and provides ErySave
         with a copy of the sublicense agreements.

                                     - 8 -
<PAGE>

5.4      The License is restricted to the Licensed Field and the CE-Approved
         Prototype and future Products and does not in any way limit or restrict
         the rights of ErySave or any third party licensee of ErySave from using
         and practising the PARSUS Technology for any purpose outside the
         Licensed Field.

6.       TRADEMARKS

6.1      All CE-Approved Prototypes and future Products or their packaging shall
         be marked with an acknowledgement that the CE-Approved Prototype or
         Product is manufactured and marketed under license from ErySave.

6.2      ATS shall, if commercially reasonable, include the ErySave name, logo
         and PARSUS trademark on the Prototypes and Products, as may be directed
         by ErySave in accordance with ErySave's corporate identity policies in
         effect from time to time or otherwise as advised by ErySave; and all
         CE-Approved Prototypes and Products shall, if commercially reasonable,
         bear such of the Trademarks as ErySave may determine. ATS shall show
         ErySave its intended uses of the Trademarks (including the ErySave
         name, logo and trademark(s)) in advance of such use, and seek ErySave's
         approval thereof, which shall not be unreasonably withheld. ATS will
         provide rationale for all instances where the ErySave name, logo or
         trademark(s) are not included on the Prototypes and Products, .after
         which ATS may sell, offer for sale, distribute and advertise the
         CE-Approved Prototype and any other Products bearing only ATS
         trademarks. ATS may, in its sole discretion, use the Trademarks along
         with ATS trademarks subject to the following restrictions set forth in
         this Part 6.

6.3      The Trademarks shall be and remain the sole and exclusive property of
         ErySave, who shall be responsible to obtain and maintain all such
         trademark registrations as deemed necessary or advantageous.

6.4      ATS shall not use the Trademarks for any article, product, goods,
         merchandise or service other than the CE-Approved Prototype and
         Products. ATS shall use the Trademarks in respect of the CE-Approved
         Prototype and Products in a manner consistent with this Agreement and
         ErySave's corporate identity policies in effect from time to time,
         without any addition, deletion, amendment or modification other than
         with ErySave's prior, written permission. ATS and ErySave are not
         authorized to use any of the Trademarks owned by the other party as a
         corporate name.

6.5      Both parties, shall conduct their respective activities at all times in
         a manner that maintains the reputation, status and goodwill of each
         parties trademarks, and neither party shall do anything that could tend
         to damage, impair or destroy the reputation, status or goodwill of the
         other's trademarks, the CE-Approved Prototype, Products or the parties
         to this Agreement.

6.6      ErySave shall have the right upon reasonable notice to inspect ATS's
         records of utilizing the Trademarks, as well as of the quality of the
         Products and Prototypes on which they are affixed or applied, and to
         require reasonable adjustment therein to the extent necessary to
         safeguard its rights under trademark law.

                                     - 9 -
<PAGE>

7.       ROYALTY AND OTHER PAYMENTS

7.1      In respect of all CE-Approved Prototypes which are being developed or
         marketed and sold by ATS or its Affiliates, ATS shall pay to ErySave on
         all Net Sales the Royalty calculated in accordance with the criteria
         set out in Appendix 1 to this agreement. The Royalty shall accrue
         whenever a CE-Approved Prototype or future Product sale is invoiced by
         ATS or its Affiliates to or otherwise becomes owing by their customers.

7.2      In respect of all permitted sub-licenses of the PARSUS Technology
         granted to independent third parties by ATS or its Affiliates relating
         to CE-Approved Prototypes, ATS shall pay to ErySave ** of all up-front,
         down payment, milestone, fee, royalties, or like payments (if any)
         receivable by ATS or its Affiliates. Such amounts shall be payable to
         ErySave within thirty (30) days from the date of receipt of such
         up-front, down payment, milestone, fee or like payment by ATS or its
         Affiliate, and ATS shall provide a monthly accounting of such receipts
         (as well as of the number of CE-Approved Prototypes or future Products
         invoiced by ATS's sub-licensees in sufficient detail as to permit
         calculation of the amounts due to ATS and its Affiliates, and the
         related calculation of the amounts due by them to ErySave), or shall
         provide a statement that no CE-Approved Prototype or future Product
         sales were invoiced and/or that no amounts were due by sublicensees to
         ATS and Affiliates. Such monthly accountings or statements shall be
         made by ATS.

7.3      The Net Sales Royalty shall be calculated and payable on a calendar
         quarterly basis in arrears commencing on the last day of the first
         calendar quarter after the first sale of a CE-Approved Prototype is
         invoiced.

7.4      Within thirty days after the end of each calendar quarter, ATS shall
         pay the Royalty. Within thirty days after the end of each calendar
         month, ATS shall provide a monthly accounting of the number of
         CE-Approved Prototypes or future Products invoiced by ATS, its
         Affiliates, and its sub-licensees in sufficient detail as to permit
         calculation of the amounts due or shall provide a statement that no
         CE-Approved Prototype or future Product sales were invoiced. Such
         accountings or statements shall be made by ATS.

7.5      ATS shall make all payments due under this Part 7 in US dollars. All of
         ATS's accruals in non-US currency shall be translated into US dollars
         at the exchange rates prevailing at the time of ATS's invoice (or
         otherwise as required by US GAAP, consistently applied), free and clear
         of and without deduction or delay in respect of any demand, set-off,
         counter claim or other dispute and, so far as legally possible, each
         such payment shall be made free and clear of any taxes imposed by or
         under the authority of any government or public authority.

7.6      ATS shall pay interest on overdue payments owing under this Part 7 at
         the rate of 1% simple interest per month (12% simple interest per
         annum) until paid.

7.7      Royalties and other payments accruing hereunder shall be paid to
         ErySave or ErySave's designated payee, named by ErySave in written
         notice to ATS.

7.8      ATS may deduct and withhold and shall remit and pay to the proper
         authority, any withholding or similar tax which ATS is required to
         deduct, withhold and remit in

                                     - 10 -
<PAGE>

         respect of Royalty on ErySave's behalf. ATS shall claim, or assist
         ErySave to do so, exemption from withholding tax on royalties, if any,
         under applicable taxation treaties. Proof of such withholding tax
         payments in a form satisfactory to the payee shall be secured and sent
         to the payee as evidence of such payment.

7.9      ATS shall at its principal place of business, during the term of this
         Agreement and for a period of three (3) years thereafter, keep true and
         accurate records of all matters connected with the development,
         manufacture and sale of CE-Approved Prototypes and shall also keep
         proper records of sales invoices and all books of account relating to
         payments from sub-licensees containing such correct entries complete in
         every particular as may be necessary to enable the amounts due to
         ErySave to be conveniently ascertained and audited.

7.10     Upon not less then ten (10) day's prior written request by ErySave, ATS
         shall produce the records and books of account referred to in paragraph
         7.9 and calculations for Cost of Goods Sold (as defined in Appendix 1)
         certified as correct by ATS or its agents and, if so requested by
         ErySave, which shall not be more than twice in any calendar year, ATS
         shall permit those records and books to be examined by an independent
         accountant nominated by ErySave and reasonably acceptable to ATS, and,
         at ErySave's expense, ATS shall permit that accountant to take copies
         of or extracts from the records and books. In addition, ATS shall give
         the independent accountant all assistance, access and facilities
         reasonably necessary to enable the independent accountant to verify the
         records and books and shall supply such other information as may be
         reasonably necessary or proper to enable the amounts payable to ErySave
         under this Agreement to be ascertained and verified. If the independent
         accountant identifies a deviation equal to or greater than ten percent
         (10%) from the amounts identified as payable to ErySave by ATS then the
         independent accountant's cost shall be paid by ATS. ATS shall
         immediately remit to ErySave any outstanding Royalty or other payments
         identified as owing and unpaid by the independent accountant and
         overdue interest thereon. If the independent accountant identifies that
         excess Royalties have been paid, such excess Royalties shall be applied
         against the Royalties owed in the next calendar quarter.

7.11     In the event that an investigation of ATS' books and records is made
         pursuant to paragraph 7.10, certain confidential and proprietary
         business information of ATS may necessarily be made available to the
         person or persons conducting such investigation. It is agreed that such
         confidential and proprietary business information shall be retained in
         confidence by ErySave, its agent or representative, and shall not be
         used by ErySave, its agent or representative, or disclosed to any third
         party other than as contemplated under this Agreement without the prior
         express written permission of ATS unless required by law. It is
         understood and agreed, however, that such information may be used in
         any proceeding based on ATS' failure to make payment of Royalties or
         other payments required under this Agreement.

8.       RIGHT OF FIRST REFUSAL

8.1      ATS is hereby granted a right of first refusal to exploit any new
         devices or products or applications for any devices or products for use
         outside of the Licensed Field but relating to the care of cardiac
         surgery patients.

                                     - 11 -
<PAGE>

8.2      In the case of each such new device or product or application for any
         new device or product, ATS's right of first refusal shall arise upon
         receipt from ErySave of written notice that such a device or product or
         application for such a device or product has been developed to at least
         the concept stage and shall expire 90 days thereafter if the parties
         are unable to reach an agreement, acting reasonably, for the further
         development and commercialization of the device or product or
         application for the device or product.

8.3      ATS is hereby granted a right of first negotiation for all healthcare
         applications not included in Section 8 above.

9.       FUTURE PRODUCT DEVELOPMENT

9.1      To the extent ATS elects to have ErySave participate in the development
         of future Products that employ the PARSUS Technology in the Licensed
         Field, the parties shall share equally the cost of all future
         development of and improvements to such future Products, including the
         cost of all patenting arising out of inventions relating to such future
         Products. If ATS does not elect to have ErySave participate, then ATS
         shall pay such costs. As indicated in Section 12.5, all such inventions
         and the associated patent and other intellectual property rights shall
         be and remain the property of ErySave and shall fall within the scope
         of the License, as provided in this Agreement. ATS and its agents,
         employees, contractors and representatives shall execute such
         assignments as ErySave may consider necessary or desirable to implement
         its property interest.

9.2      To the extent ATS elects to have ErySave participate in the development
         of such future Products, the parties shall consult with one another
         regarding such future Product development work and shall, acting
         reasonably, establish agreed plans and budgets for such work.

9.3      Neither party shall acquire any rights in the other party's
         intellectual property or other proprietary rights or technology with
         respect to any future Products except as explicitly set forth by
         written agreement executed by both parties.

10.      ERYSAVE'S REPRESENTATIONS, OBLIGATIONS, INDEMNITY AND DISCLAIMER

10.1     ErySave shall provide to ATS, in useable form, all Know-How in
         existence as of the Effective Date and reasonable technical support,
         information, ongoing research, and any other later acquired Know-How
         for future Product developments referred to in paragraph 9.1, to the
         extent ErySave has such technical information and research, but ErySave
         shall have no obligation to create or develop technical information or
         research for ATS.

10.2     ErySave shall provide such other or additional assistance to ATS in the
         form of promotion and training on the use of the CE-Approved Prototypes
         or future Products as ATS may from time to time reasonably request and
         ATS shall reimburse and remunerate ErySave for such assistance as the
         parties may from time to time agree, provided that ErySave shall have
         no obligation to provide such support in the absence of agreement as to
         its reimbursement and remuneration or due to lack of availability of
         ErySave staff or other resources.

10.3     ErySave represents and warrants that it has the sole, exclusive and
         unencumbered right to grant the licences and rights herein granted to
         ATS, and that it has not granted any

                                     - 12 -
<PAGE>

         option, licence, right or interest in or to the PARSUS Technology to
         any third party which would conflict with the rights granted by this
         Agreement.

10.4     ErySave represents and warrants that, insofar as it is aware, the
         PARSUS Technology, Patents, Know-How, or Trademarks do not infringe or
         misappropriate any patent, trademark, copyright, mask right, moral
         right, trade secret or other industrial, intellectual or proprietary
         rights of any third party ("Third Party IP Rights").

10.5     ErySave shall defend, indemnify and hold harmless ATS and its
         directors, officers, employees and agents from all claims, suits,
         demands, losses, costs, attorney's fees, damages, and loss of profits
         in any way connected with, caused by, resulting from or related to: (i)
         information, materials, components or items provided, developed or
         produced by ErySave to the extent attributable to such provision,
         development or production; or (ii) breach of any term or condition of
         this Agreement; or (iii) any warranty made by ErySave under this
         Agreement; but excluding any claims, suits, losses, costs, attorney's
         fees, damages, and loss of profits or part thereof to the extent based
         solely on ATS's negligence or breach of this Agreement or the
         negligence of any third party acting by, through or under ATS or to the
         extent arising from ATS's operations or actions. ErySave shall conduct
         the defense in any such third party action arising as described herein
         and ATS shall cooperate with such defense, at the expense of ErySave,
         provided that ErySave reasonably consults with ATS. ATS may, at its own
         expense, assist in such defense if it so chooses, provided that ErySave
         will control such defense and all negotiations relative to the
         settlement of any such claim. Notwithstanding any of the foregoing,
         ErySave shall not settle any such claim without ATS' prior written
         consent, which consent will not be unreasonably withheld.

10.5.1   If, under this Agreement, any Product or any part thereof, which
         becomes the subject of any claim, suit or proceeding for infringement
         or misappropriation of any Third Party IP Rights, or if any Products,
         or any part thereof, is held or otherwise determined to infringe or
         misappropriate any Third Party IP Rights, then ErySave will at its
         expense, and without limiting its other obligations under this
         Agreement, achieve the following results in the listed order of
         preference:

                  (i)   Secure for ATS the right to continue using and
                        practising the PARSUS Technology and to continue
                        manufacturing, importing, marketing, distributing,
                        selling and using the Products or any part thereof to
                        the fullest extent consistent with the License granted
                        by this Agreement;

                  (ii)  Replace or modify the Products, or any part thereof, to
                        make the Products non-infringing but without degradation
                        in operation, performance, or utility; or

10.5.2   Notwithstanding anything to the contrary set forth in this Agreement,
         ErySave has no liability for misappropriation or infringement of any
         Third Party IP Rights arising from: (i) ErySave's compliance with any
         designs, specifications or instructions of ATS; (ii) modification of
         the Product by ATS or its representatives without the prior knowledge
         and written approval of ErySave; or (iii) use of the Product by ATS in
         violation of this Agreement or not in accordance with instructions for
         use.

                                     - 13 -
<PAGE>

10.6     Except as otherwise provided in this Agreement, ErySave makes no other
         representation or warranty (including any warranty of merchantability
         or fitness for a particular purpose) to ATS or anyone else with respect
         to the use of the PARSUS Technology or the development, manufacture,
         use, marketing, distribution, and sale of Products pursuant to this
         Agreement and except as otherwise provided in this Agreement disclaims
         all liability in connection therewith, including liability for special,
         incidental, consequential or penalty damages, including for lost
         profits or goodwill, even if advised of the possibility thereof.

11.      ATS'S REPRESENTATIONS, OBLIGATIONS AND INDEMNITY

11.1     ATS shall indemnify and save harmless ErySave and its directors,
         officers, employees and agents from all claims, suits, actions,
         judgments, losses, costs, expenses, attorney's fees, damages, and loss
         of profits in any way connected with, caused by, resulting from or
         related to: (i) information, materials, components or items provided,
         developed or produced by ATS, or (ii) breach of any term or condition
         under this Agreement; or (iii) breach of any warranty made by ATS under
         this Agreement; but excluding any claims, suits, losses, costs,
         attorney's fees, damages, and loss of profits or part thereof based
         solely on ErySave's negligence or breach of this Agreement or the
         negligence of any third party acting by, through or under ErySave. ATS
         shall conduct the defense in any such third party action arising as
         described herein and ErySave shall cooperate with such defense, at
         ATS's expense, provided that ATS reasonably consults with ErySave.
         ErySave may, at its own expense, assist in such defense if it so
         chooses, provided that ATS will control such defense and all
         negotiations relative to the settlement of any such claim.
         Notwithstanding any of the foregoing, ATS shall not settle any such
         claim without ErySave's prior written consent, which consent will not
         be unreasonably withheld.

11.2     ATS shall obtain and carry in full force and effect commercial, general
         liability and product liability insurance which shall protect ATS and
         ErySave with respect to events covered by paragraph 11.1. Such
         insurance shall be written by a reputable insurance company authorized
         to do business in the State of Minnesota, USA and the country of
         Sweden, shall list ErySave as an additional named insured thereunder,
         shall be endorsed to include product liability coverage and shall
         require thirty (30) days written notice to be given to ErySave prior to
         any cancellation or material change thereof. The limits of such
         insurance shall not be less than Three Million Dollars ($3,000,000 USD)
         per occurrence with an aggregate of Ten Million Dollars ($10,000,000
         USD) for personal injury or death, and Three Million Dollars
         ($3,000,000 USD) per occurrence with an aggregate of Ten Million
         Dollars ($10,000,000 USD) for property damage. Upon request, ATS shall
         provide ErySave with certificates of insurance evidencing the same.

11.3     ATS warrants that it will substantially follow all applicable
         standards, specifications, laws, regulations, guidelines and rules
         relating to the development, manufacture, use, distribution and sale of
         Products.

11.4     Except with respect to obtaining CE Certification for the Products, ATS
         shall be responsible for obtaining all approvals, authorisations,
         permissions or licenses necessary or desirable to enable the Products
         to be used in its business operations. ErySave shall be provided with
         copies of all such approvals, etc. and any associated filings and
         information provided to and received from applicable authorities.

                                     - 14 -
<PAGE>

12.      INTELLECTUAL PROPERTY RIGHTS

12.1     Subject to this paragraph, ErySave shall take all steps necessary to
         file, prosecute and maintain the validity and subsistence of the PARSUS
         Technology and the Know-How and Patents. In each case that ErySave
         decides not to file, prosecute and maintain any patent application or
         patent for any PARSUS Technology in the Licensed Field, it shall
         promptly notify ATS and ATS shall have the option thereafter to file,
         prosecute and maintain such patent applications or patents in and to
         any PARSUS Technology itself. ErySave will do all acts and execute all
         documents reasonably necessary for the purposes of this paragraph. If
         ATS so files, prosecutes or maintains, then 50% of any reasonable
         attorney's fees, government fees and expenses incurred by ATS in
         filing, prosecuting and maintaining any Patents, Trademarks or Know-How
         shall be applied against and reduce any future Royalties or other
         payment(s) otherwise payable to ErySave under this Agreement.

12.2     ATS shall not do any act (or fail to act) so as to reduce the rights of
         ErySave in the PARSUS Technology.

12.3     Other than as expressly provided for in this Agreement, nothing in this
         Agreement shall be construed as granting either party any right or
         license, either express or implied, under any patents or other
         industrial or intellectual property right, including trade secrets and
         know-how, of the other party.

12.4     ErySave shall own all right, title and interest in, to and associated
         with any improvement, development, discovery or invention or any future
         Products as it relates to and employs the PARSUS Technology, whether
         made by ErySave or any ErySave employee, or ATS or ATS employee or any
         third party during the term of and in connection with this Agreement,
         including any intellectual property rights, know-how, trade secrets,
         inventions, data and information, but then any such improvement,
         development, discovery, invention, data and information, and any
         intellectual property rights, know-how, trade secrets thereto shall be
         subject to the License.

12.5     Each party shall, within 30 days of becoming aware of any complaint,
         claim or allegation that the exercise of the rights under this
         Agreement constitutes an infringement or misappropriation of any Third
         Party IP Rights, give the other party written notice of such claim,
         etc. Likewise, each party shall, within 30 days of acquiring knowledge
         or reasonable belief that any third party is infringing or
         misappropriating any Patents, Trademarks or Know-How, give the other
         party written notice of such knowledge or reasonable belief.

12.6     Any prosecution against third party infringers of ErySave Patents or
         Know-how shall be conducted by ErySave, upon consultation with ATS. The
         parties shall equally share the costs of, all claims and legal
         proceedings against third parties relating to third party infringement
         of any Patents or Know-How in the Licensed Field, and the benefits of
         such proceedings (after reimbursement to the parties of their
         respective legal and court costs thereof) shall be shared equally
         between them.

12.7     If either party elects not to participate in a proceeding referred to
         in paragraph 12.7 it shall notify the other party within ninety (90)
         days of giving or receiving notice pursuant to paragraph 12.6, the
         other may elect to proceed alone and shall have the right to

                                     - 15 -
<PAGE>

         institute or defend proceedings in its own name and at its own expense
         and shall be entitled to receive all benefits derived therefrom,
         subject to, in the case where ATS is the continuing party, remaining
         liable to pay Royalty on all such benefits that are intended to
         compensate for lost or reduced Product sales or similar loss or damage.
         The non-participating party shall, if so requested in writing by the
         continuing party, lend all necessary support to the proceedings on
         condition that the continuing party indemnifies it against all costs,
         damages and expenses which may be incurred in so doing.

12.8     Neither party shall settle or compromise any proceedings under this
         Part 12 without the consent of the other party if the settlement or
         compromise obliges the other party to make any payment or part with any
         property or other right or assume any obligation or grant any licence
         or other rights or be subject to any injunction or other restraint by
         reason of such settlement or compromise.

13.      CONFIDENTIALITY

13.1     In this Part 13 the following terms shall have the following meanings
         whenever such terms are used in their capitalised form:

13.1.1   Confidential Information means any information which was not or is not
         in the public domain at the time of its disclosure and which is
         communicated in any way or form by either party to the other, either
         before or after the date of this Agreement, whether or not such
         information is identified as confidential, including, without
         limitation, information relating to products, processes, services,
         businesses, personnel, research, commercial activities, formulas,
         substances, materials, programmes, devices, concepts, inventions,
         patents, designs, methods, techniques, marketing and commercial
         strategies, data, trade secrets, know-how, plans, operations, tests,
         studies, manuals, market reports, customers, financial status, and the
         like.

13.1.2   Disclosing Party means the party making disclosure of or otherwise
         communicating Confidential Information to the other party.

13.1.3   Recipient means the party receiving or otherwise obtaining Confidential
         Information from the other party.

13.2     The provisions of this Part 13 shall supersede and replace any
         confidentiality agreement previously entered into between the parties
         regarding the subject matter of this Agreement.

13.3     Confidential Information shall be and remain the property of the
         Disclosing Party. The Recipient shall obtain no right of any kind in
         Confidential Information other than the right to use it for the
         purposes consistent with this Agreement.

13.4     Confidential Information shall be used by the Recipient only for the
         purposes consistent with this Agreement and for no other use or purpose
         so long as the Confidential Information is subject to this Agreement.

13.5     Confidential Information shall be kept strictly confidential by the
         Recipient and shall not be disclosed to any third party by the
         Recipient, other than with the prior, written

                                     - 16 -
<PAGE>

         permission of the Disclosing Party or as may be required by law or
         under appropriate confidentiality obligations.

13.6     The Recipient may disclose Confidential Information only to those of
         its directors, officers, employees and agents, including permitted
         contractors, who are necessarily and directly involved in, and who need
         to know of the Confidential Information as an essential part of,
         performing the Recipient's obligations under this Agreement; and the
         Recipient shall ensure that they enter into a confidentiality agreement
         with the Recipient covering the disclosed Confidential Information on
         terms no less onerous than those of this Part 13, that they use the
         Confidential Information only for the purposes of this Agreement and
         that they do not make any copies of or extracts from the Confidential
         Information, except as authorised by the Disclosing Party in writing or
         as necessitated by the requirements of this Agreement.

13.7     In the event the Recipient is required to make disclosure of
         Confidential Information under the compulsion of law or authority, the
         Recipient shall promptly inform the Disclosing Party and shall
         cooperate with the Disclosing Party, but at no cost to Recipient, in
         order to enable the Disclosing Party to take such action as it deems
         necessary or appropriate to avoid or minimize the disclosure of such
         Confidential Information.

13.8     In the event of any unauthorised disclosure of Confidential
         Information, the Recipient shall immediately inform the Disclosing
         Party and shall co-operate with it in determining what steps should be
         taken.

13.9     The obligations of confidence, non-use and non-disclosure set out in
         this Part 13 shall not apply to any information that is:

         (a)      information which the Recipient can establish was known to the
                  Recipient prior to its disclosure hereunder;

         (b)      information which is or becomes generally available to the
                  public through no act or omission of the Recipient;

         (c)      information which is rightfully received by the Recipient from
                  a third party who is not under an obligation of
                  confidentiality; or

         (d)      information which is specifically released, in writing, from
                  the scope of this Agreement by the Disclosing Party.

13.10    Upon the expiry or termination of this Agreement, the parties shall
         each immediately return to the other all Confidential Information
         received from the other in whatever form and all copies thereof.

13.11    The obligations of the parties under this Part 13 shall survive the
         expiry or termination of this Agreement and shall remain binding upon
         the parties, unless otherwise agreed, for a period of five (5) years
         thereafter.

14.      TERM

14.1     This Agreement shall remain in full force and effect, unless earlier
         terminated in accordance with the provisions of this Agreement, until
         the expiry of the last to expire

                                     - 17 -
<PAGE>

         patent right which makes up the Patents or until the Know-How is no
         longer confidential, whichever is the longer.

15.      EARLY TERMINATION

15.1     Breach. If either party is in material default or breach of any of its
         representations, covenants or obligations under this Agreement, the
         other party may give notice of such breach to the defaulting party
         requesting the latter to remedy the default or breach and stating the
         intention of the notifying party that this Agreement should terminate
         in the event the other party fails to remedy the breach or default. If
         the defaulting party fails to remedy the breach within sixty (60) days
         after the date of notice, then this Agreement shall terminate
         immediately upon the expiry of the sixty day period.

15.2     Insolvency. This Agreement shall terminate immediately if ATS shall
         become insolvent or bankrupt, or if a receiver shall be voluntarily or
         involuntarily appointed to direct its business for the benefit of
         creditors or otherwise.

15.3     CE Certification. If CE Certification for the Prototype is not obtained
         within thirty-six (36) months from the date of execution of this
         Agreement, ATS may terminate this Agreement by written notice of such
         termination given within the 30 days following the end of such 36th
         month.

15.4     ATS Challenge to Patents. In the event ATS disputes or challenges the
         validity or subsistence of any of the patent rights which make up the
         Patents, ErySave may terminate this Agreement upon ninety (90) days'
         written notice to ATS in respect of each such patent right or in
         respect of this entire Agreement, in ErySave's discretion, unless ATS
         withdraws or abandons such dispute or challenge to any of the patent
         rights which make up the Patents with that ninety (90) day period.

15.5     Effects of termination

         (a) Goodwill, etc. After Termination or Expiration. In the event of
         termination of this Agreement under this Part 15, or in the event of
         expiration, ATS shall have no claim, right or entitlement to any
         compensation for the loss of any right, advantage or goodwill
         associated with this Agreement and all rights granted to ATS under this
         Agreement, and all rights granted by ATS to any sub-licensee, shall
         cease and they shall forthwith cease any further use, practise under or
         exploitation of the Technology, provided however they shall be entitled
         for a period of three (3) months after the date of termination to
         dispose of any stock of Products in existence at the date of
         termination, subject to the payment of Royalty and other amounts due in
         respect thereof.

         (b) No Prejudice of Accrued Rights. Termination or expiration of this
         Agreement, for whatever cause, shall be without prejudice to the rights
         of the parties accrued under this Agreement up to the date of
         termination.

         (c) Termination for ATS's Breaches of Certain Marketing Obligations
         Entails Payment by ErySave. If ATS fails to meet the performance
         criteria set out in one of sub-paragraphs 3.14a-h within 60 days of
         receipt of written notice from ErySave that such performance criteria
         has not been met, despite ATS's having attempted in good faith to
         perform, and if as a consequence, ErySave obtains the right to
         terminate this Agreement

                                     - 18 -
<PAGE>

         under Section 15.1 ErySave must pay to ATS one half of the total sum
         paid to ErySave by ATS pursuant to paragraph 2.5. This provision shall
         not apply if ATS has also failed to meet the performance criteria in
         subparagraph 3.14(i).

         (d) No Use of Trademarks After Termination. Upon the expiry or
         termination of this Agreement, regardless of the reasons for
         termination, ATS's licence under paragraph 5.2 shall terminate, and ATS
         shall cease using the Trademarks and shall have no claim to the
         Trademarks or any right or property in the intangibles or goodwill of
         the Trademarks.

16.      MISCELLANEOUS

16.1     For good and valid commercial reasons, the parties shall keep the terms
         of this Agreement confidential and shall make no disclosure of its
         contents other than as may be agreed by both parties in writing,
         required by law, or required by either party to enforce its rights
         hereunder. However, both parties have the right to disclose the
         agreement to financial institutions, given that a valid Non Disclosure
         Agreement has been signed.

16.2     If any provision of this Agreement should as a matter of law be or
         become void or unenforceable, this Agreement shall be construed as if
         such provision was not contained herein and the remainder of this
         Agreement shall remain in full force and effect.

16.3     In the event that any strike, lockout, other industrial disturbance,
         epidemic, landslide, lightning, earthquake, fire, storm, flood,
         drought, other act of God, rebellion, war, civil disturbance, act of
         terrorism, explosion, or act or decision of any governmental authority
         or court of law renders impossible the performance of any of the
         obligations of the parties or either of them under this Agreement, the
         party or parties affected shall be excused the performance of the
         relevant obligation or obligations upon notifying the other party in
         writing, giving a detailed explanation of the occurrence in question.
         Upon the giving of such a notice, the performance of the party giving
         notice shall be abated only to the extent and for so long as
         performance remains impossible. Except for the payment of money,
         neither party shall be required to make up any performance that is
         abated in accordance with this paragraph.

16.4     This Agreement may not be assigned by either party, other than to an
         Affiliate of the party, without the prior, written permission of the
         other party which consent shall not be unreasonably withheld, except
         that ErySave and ATS may assign the agreement to any third party that
         acquires substantially all its assets or of its shares and also may
         assign to a wholly owned subsidiary.

16.5     During the term of this Agreement, Erysave and ATS shall not develop,
         manufacture, produce, market, distribute, sell, handle, acquire an
         interest in, or become involved, with any product, or service, which
         directly or indirectly competes with Products' or which in any way
         conflicts or could conflict with their obligations under this
         agreement, other than with prior written permission of the other party.
         Any violation should of this paragraph would constitute a breach of the
         agreement.

16.6     In entering into and carrying out their obligations under this
         Agreement, the parties are independent contractors and shall have no
         power or authority, express or implied, to bind the other party, act on
         the other party's behalf, or in any way enter into or incur any

                                     - 19 -
<PAGE>

         liability for or on behalf of the other party, and nothing in this
         Agreement shall be construed as giving rise to a relation of
         partnership or agency between the parties.

16.7     Any disagreement or dispute which may arise between the parties in
         relation to or connection with this Agreement shall be settled amicably
         and expeditiously by good faith negotiation. Any such dispute, other
         than non-payment by ATS to ErySave of any amount or amounts owing under
         this Agreement, which cannot be so settled within 60 days after the
         commencement of negotiation shall be referred to non-binding mediation
         by a single, independent mediator who is an expert in the field of
         medical product development to be appointed by agreement of the
         parties. Any such dispute which cannot be so settled within 90 days of
         the cessation of the time for negotiation shall be referred to and
         finally settled by arbitration by three arbitrators, one to be
         appointed by each party and the third to be appointed by the first two,
         in accordance with the international commercial arbitration rules of
         the London Court of International Arbitration. All decisions,
         determinations and rulings of the arbitrators shall be final and shall
         be fully and irrevocably accepted by the parties. Any such arbitration
         shall be held in London, England in the English language. The parties
         shall use their best efforts to conduct all dispute resolution
         procedures under this Agreement as expeditiously, efficiently and
         cost-effectively as possible.

16.8     This Agreement shall be governed by the laws of England in respect of
         all matters, including without limitation the execution, interpretation
         and performance of this Agreement.

16.9     All notices and payments required or permitted by this Agreement shall
         be delivered to the relevant party as noted in Part 1, and either party
         may, in writing, change the address to which notices may be given.

16.10    This Agreement constitutes the entire agreement between the parties
         concerning the subject matter of this Agreement and any representation,
         promise or condition not incorporated in this Agreement shall not be
         binding upon either party. No amendment, modification or addition to
         this Agreement shall be binding on the parties unless made in writing
         and executed by both parties.

16.11    The waiver on the part of either party of any right or interest
         hereunder shall not imply the waiver of any other right or interest or
         any subsequent waiver.

16.12    In the event ATS and ErySave elects to develop additional Products in
         any related development process, the parties will follow a similar
         commercial phase procedure with specific terms, conditions and
         requirements to be determined by mutual agreement of the parties. `

                                     - 20 -
<PAGE>

IN WITNESS WHEREOF the parties have executed two (2) copies of this Agreement,
each of which shall be considered an original.

ATS MEDICAL INC                             ERYSAVE AB

_____________________________________       ___________________________________
MICHAEL DALE                                HENRIK JONSSON
CEO                                         CEO
April 26th 2004                             April 26th 2004

_____________________________________       ___________________________________
RICHARD CURTIS                              LENNART SJOLUND
VP Marketing Business development           Chairman
April 26th 2004                             April 26th 2004

                                     - 21 -
<PAGE>

APPENDIX 1 CALCULATION OF ROYALTY

ROYALTY IS THE SHARE OF GROSS PROFITS ATTRIBUTABLE TO ERYSAVE PURSUANT TO THE
FOLLOWING:

1. PRODUCT DISPOSABLE KITS

A. WHERE ATS SELLS THE DISPOSABLES DIRECTLY:

-     ErySave and ATS will ** all Gross Profit **. Gross Profit shall be defined
      as: Net Sales less Cost of Goods Sold less the ATS Fee. The ATS Fee shall
      be defined as ** of Net Sales until cumulative Net Sales under this
      Agreement reach **, then ** of Net Sales until cumulative Net Sales exceed
      **, and then ** of Net Sales thereafter. Cost of Goods Sold shall be
      calculated as determined in accordance with the US generally accepted
      accounting principles, consistently applied, followed by ATS. Cost of
      Goods Sold shall include the following costs of ATS related only to the
      Product(s): raw materials, direct labor including wages and benefits,
      sub-contract purchases, indirect labor, factory overhead, depreciation,
      facility overhead, supplies, bad debt expense and freight in.

            -     Example 1

<TABLE>
<CAPTION>
                                Sales <**          Sales **         Sales >**
<S>                             <C>                <C>              <C>
Net Sales amount                **                 **               **
ATS Fee                         **                 **               **
Cost of Goods Sold              **                 **               **
Gross Profit                    **                 **               **
Royalty                         **                 **               **
</TABLE>

            -     Example 2

<TABLE>
<CAPTION>
                                Sales <**          Sales **         Sales >**
<S>                             <C>                <C>              <C>
Net Sales amount                **                 **               **
ATS Fee                         **                 **               **
Cost of Goods Sold              **                 **               **
Gross Profit                    **                 **               **
Royalty                         **                 **               **
</TABLE>

B. WHERE ATS USES SUB-DISTRIBUTORS TO SELL DISPOSABLE:

-     ErySave and ATS will ** all Gross Profit **. Gross Profit shall be defined
      as: Net Sales from amounts invoiced to sub-distributors less ATS's Cost of
      Goods Sold less the ATS Fee. The ATS Fee is defined as ** of Net Sales
      regardless of cumulative sales growth. Cost of Goods Sold shall be
      calculated as first described above. In the case that gross profit is
      negative ErySave will not have to cover any loss.

            -     Example
<TABLE>
<S>                             <C>
Net Sales amount                **
ATS Fee                         **
Cost of goods                   **
Gross profit                    **
Royalty                         **
</TABLE>

                                     - 22 -
<PAGE>

-       If any other model is used for a sub-distributor, ATS shall notify
        ErySave in advance and obtain ErySave's consent, including agreement as
        to the calculation of Royalty, before ATS signs an agreement with the
        sub-distributor.

2. PRODUCT DEVICES

A. WHERE ATS SELLS THE DEVICES DIRECTLY:

-     ErySave and ATS will ** all Gross Profit **. Gross Profit shall be defined
      as: Net Sales less Cost of Goods Sold less the ATS Fee. Cost of Goods Sold
      shall be calculated as first described above. The ATS Fee shall be defined
      as ** of Net Sales. In the case that gross profit is negative ErySave will
      not have to cover any loss.

            -     Example

<TABLE>
<S>                             <C>                <C>              <C>
Net Sales amount                **                 **               **
ATS Fee                         **                 **               **
Cost of Goods Sold              **                 **               **
Gross Profit                    **                 **               **
Royalty                         **                 **               **
</TABLE>

B. WHERE ATS USES SUB-DISTRIBUTORS TO SELL DEVICES:

-     ErySave and ATS will ** all Gross Profit **. Gross Profit shall be defined
      as: Net Sales less Cost of Goods Sold less the ATS Fee. Cost of Goods Sold
      shall be calculated as first described above. The ATS Fee is defined as **
      of Net Sales regardless of cumulative sales growth. In the case that gross
      profit is negative ErySave will not have to cover any loss

            -     Example

<TABLE>
<S>                             <C>                <C>              <C>
Net Sales amount                **                 **               **
ATS Fee                         **                 **               **
Cost of Goods Sold              **                 **               **
Gross Profit                    **                 **               **
Royalty                         **                 **               **
</TABLE>

                                     - 23 -
<PAGE>

                                   APPENDIX 2

                                   TRADEMARKS

                                     PARSUS

                                   MindShield

                                     ErySave

                                     - 24 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]